North Carolina Clinical Trials

A listing of North Carolina Clinical Trials actively recruiting patient volunteers.

Charlotte, Raleigh, Asheville, and Wilmington are the key cities of North Carolina, with the Charlotte metro area alone holding about 2.56 million residents and attracting the most tourists each year. The state's diverse economy is driven in part on very high availability of hydroelectric power, and it has 15 metropolitan areas overall. Blue Ridge Parkway and Great Smoky Mountains National Park rank as the most visited national park and public land unit, respectively, in the whole United States. The 200-mile Outer Banks make up the most popular beaches. Duke University Hospital, a renowned academic medical center, has nearly 1,000 beds.

Search by Name
Search
Filter by Condition
2823 trials found

Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2

NCT05438498

If a treated cancer patient cannot make antibodies to a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Emergency Use Authorization (EUA) or approved vaccine, their risk for infection and its sequelae are significantly increased. The Astra-Zeneca Immuno-Suppressed Program (AISP) is designed to address whether a patient treated for cancer who receives a single-dose of Evusheld (AZD7442) 600 mg IM or IV will maintain a stable/protective effect against symptomatic SARS-CoV-2 infection ...

Conditions: SARS-CoV-2 Infection

Multicenter Clinical Study of the SING-IMT in Patients With Late-stage AMD

NCT05438732

The objective of this study is to determine the safety and effectiveness of the smaller incision, new generation (SING), implantable miniature telescope (IMT) in patients with moderate-severe central vision loss due to late-stage age-related macular degeneration (AMD).

Conditions: Age-Related Macular Degeneration, Geographic Atrophy
Phase: Not Applicable

Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS)

NCT05441826

Phase 2, multi-center, proof-of-concept study to evaluate the safety and efficacy of VB119 on the maintenance of remission and duration of response in adults with primary MCD or primary FSGS who previously responded to steroid therapy.

Conditions: Minimal Change Disease, Focal Segmental Glomerulosclerosis

Evaluation of the Acceptability, Appropriateness, and Feasibility/Usability of a Metastatic Breast-cancer Specific Prognostic Calculator Among Clinicians

NCT05440929

I this qualitative study, Investigators will conduct semi-structured interviews with clinicians that are involved in the care of patients with breast cancer to evaluate the acceptability, appropriateness, and feasibility/usability of a metastatic breast cancer-specific prognostic tool. These interviews will be conducted by the UNC CHAI Core and will continue until thematic saturation (estimated 10 participants). The investigators will code the qualitative data using emerging themes, guided by a ...

Conditions: Metastatic Breast Cancer, End of Life

Internal Jugular Vein Compression Collar for Novel Symptomatic Treatment of Venous Pulsatile Tinnitus

NCT05441540

This study seeks to pilot an evaluation of whether an external jugular vein compression collar approved by the FDA for contact sports can provide symptomatic relief of venous pulsatile tinnitus. Furthermore, the study will evaluate quality of life impacts of the device and adherence by users.

Conditions: Pulsatile Tinnitus
Phase: Not Applicable

Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy

NCT05440643

This clinical research study investigates the safety and tolerability of a peanut SLIT-tablet.

Conditions: Peanut Allergy

Improving Balance and Energetics of Walking Using a Hip Exoskeleton

NCT05447884

Robotic lower limb exoskeletons aim to improve or augment limb functions. Automatic modulation of robotic assistance is very important because it can increase the assistive outcomes and guarantee safety when using exoskeletons. However, this automatic assistance adjustment is challenging due to person-to-person and day-to-day variations, as well as the time-varying complex human-machine-interaction forces. In recent years, human-in-the-loop optimization methods have been investigated to reduce ...

Conditions: Stroke
Phase: Not Applicable

Continued Access Study VIG Anastomotic Connector

NCT05448950

The continued access study of the VIG (hereafter referred to as the 'Venous InterGraft Continued Access Study, or 'VIG-CAS') allows for continued enrollment of subjects while the marketing application is being prepared and subsequently reviewed by FDA. The VIG-CAS will include the same patient population, follow-up schedule, and study endpoints as the VIG-only study.

Conditions: Dialysis Access Malfunction
Phase: Not Applicable

A Phase 2 Double-masked Study of VVN539 in Subjects With Elevated Intraocular Pressure

NCT05451329

This is a prospective, parallel-comparison, multi-center, double-masked, randomized, vehicle-controlled dose-response study assessing the safety and ocular hypotensive efficacy of VVN539 in subjects with POAG or OHT. Three different dosing regimens (once a day [q.d.] in the morning, q.d. in the evening and twice a day [b.i.d.]) will be tested for 7-9 days, each.

Conditions: Glaucoma, Open-Angle

A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

NCT05451810

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma. The purpose of this study is to assess the safety of epcoritamab in adult participants in relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL) or R/R follicular lymphoma (FL). Adverse events will be assessed. Epcoritamab is an investigational drug being developed for the treatment of ...

Conditions: Diffuse Large B-Cell Lymphoma, Follicular Lymphoma

A Phase 1b/2 Trial of the Safety and Microbiological Activity of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized With Pseudomonas Aeruginosa

NCT05453578

This is a phase 1b/2 study of a single dose of intravenous (IV) bacteriophage in males and non-pregnant females, at least 18 years old, diagnosed with Cystic Fibrosis (CF). This clinical trial is designed to assess the safety and microbiological activity of bacteriophage product WRAIR-PAM-CF1, directed at Pseudomonas aeruginosa in clinically stable CF individuals chronically colonized with P. aeruginosa. WRAIR-PAM-CF1 is a 4 component anti-pseudomonal bacteriophage mixture containing between 4 x ...

Conditions: Bacterial Disease Carrier, Cystic Fibrosis
Phase: Phase 1/2

A Study of JNJ-75276617 in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

NCT05453903

The purpose of this study is to determine the recommended Phase 2 dose (RP2D) candidate(s) of JNJ-75276617 in combination with AML directed therapies (dose selection) and further to evaluate safety and tolerability of JNJ-75276617 in combination with AML directed therapies at the RP2D(s) (dose expansion).

Conditions: Leukemia, Myeloid, Acute